Logo

Twist Bioscience: Siyuan Chen, Aaron Sato, Paula Green, and Angela Bitting

Feb 03, 2021

Twist Bioscience announced the promotion of Siyuan Chen to chief technology officer. Chen was previously senior director of research development. In an expansion of that role, he will outline Twist's technological vision and implement strategies to provide competitive advantages in product and market opportunity. Prior to Twist, he worked in R&D at Agilent Technologies. Chen holds a PhD in chemistry from the University of Wisconsin-Madison.

The firm has also promoted Aaron Sato to the company-wide role of chief scientific officer. In addition to continuing his role as CSO of Twist Biopharma, he will handle new custom protein and cell-based products, including high-throughput IgG antibodies. Before joining Twist in 2018, he was CSO of LakePharma.

Angela Bitting has joined Twist as senior VP of corporate affairs. She has consulted for Twist on external communications for six years as head of her own firm. Her purview will also include investor relations and internal communications.

In addition, Paula Green has been promoted to senior VP, human resources at Twist.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.